US-based microbiome therapeutics developer Finch Therapeutics obtained $90m in series D capital on Thursday from investors including medical services provider SymBiosis and quantitative trading firm Susquehanna International Group (SIG).
Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, OMX Ventures, Avenir Growth Capital, OCV Partners, Shumway Capital, Trans-Pacific Technology Fund (TPTF) and Willett Advisors also took part in the transaction.
Finch is developing drugs that restore the microbiome to treat conditions with a serious unmet medical need. Its pipeline includes CP101, a therapy to prevent recurrent C. difficile infection – symptoms of which include diarrhoea, fever and abdominal pain.
The company is also working on a therapy for autism spectrum disorder (FIN-211), chronic hepatitis B and, in partnership with pharmaceutical firm Takeda, for ulcerative colitis and Crohn’s disease.
The money will enable Finch to advance its lead asset, CP101, through the final stages of clinical development regulatory submission for C. difficile infection. The company also plans to initiate phase 1b trials for FIN-211 and for CP101 as a treatment for chronic hepatits B.
SymBiosis and SIG previously backed a $53m series C round for Finch in August 2019, when TPTF, OCV Partners, Avenir Growth Capital, Shumway Capital, Morgan Noble and Willett Advisors also invested.
Avenir, Morgan Noble, Willett Advisors and Shumway had already backed a $36m series B round in early 2018 that included unnamed additional participants.
Finch raised $5.6m in a series A round in 2017 led by Flight Partners Management and backed by Anna Maria and Stephen Kellen Foundation, Draper Richards Kaplan Foundation and angel investors Neil and Anna Rasmussen.
